The Functional 13 Protocol: Why These 13 Compounds Form the Ideal Starting Point for Integrative Cancer Support

Across the landscape of integrative oncology, hundreds of compounds have demonstrated anti-cancer activity in preclinical models, case reports, and clinical observations. The challenge for patients and practitioners alike is not a shortage of options — it is knowing where to start. The Functional 13 Protocol solves this problem by identifying 13 compounds that, taken together, address the broadest possible range of cancer's core biological vulnerabilities simultaneously.

This is not a protocol built around a single mechanism or a single cancer type. It is a multi-target, multi-mechanism framework — designed to apply meaningful biological pressure across the hallmarks of cancer that all tumor types share, while remaining safe, accessible, and affordable enough to sustain long-term. Each of the 13 compounds was selected because it contributes something the others do not, creating a synergistic stack where the whole is greater than the sum of its parts.

This article explains the rationale behind each compound's inclusion, how they work together as a system, and how additional supplements and repurposed pharmaceuticals can be layered on top for cancer-specific personalization.

The Hallmarks of Cancer: What the Protocol Must Address

In 2000, Hanahan and Weinberg published their landmark paper identifying the core biological capabilities that all cancers acquire during development — the "Hallmarks of Cancer." An updated framework (2022) now includes 14 hallmarks. An effective integrative protocol must address as many of these as possible simultaneously:

No single compound addresses all 14 hallmarks. The Functional 13 Protocol, taken as a system, covers all of them — often through multiple redundant mechanisms, providing resilience against cancer's ability to develop resistance to any single intervention.

The Signaling Pathways Cancer Hijacks

Cancer does not follow a single pathway. Researchers have identified 10 core canonical signaling pathways and roughly 12 main cellular pathways that are frequently altered across hundreds of different cancer types. Rather than a fixed number of total routes, cancer develops when genetic mutations disrupt these standard biological networks — the systems that control how cells grow, divide, and survive.

The 10 Core Canonical Pathways

Large-scale genomic studies — including those from The Cancer Genome Atlas (TCGA) — group frequent cancer-driving alterations into 10 primary signaling pathways:

How Pathways Converge

While these 10 to 12 pathways are standard biological categories, they interact, crosstalk, and mutate in thousands of unique combinations. A single tumor typically contains mutations across 2 to 8 driver genes, creating a customized and chaotic pathway profile specific to that patient's cancer. This is precisely why a multi-target, multi-mechanism protocol — one that applies pressure across multiple pathways simultaneously — is more strategically sound than any single-agent approach.

The Functional 13 Protocol is designed with this complexity in mind. Each compound was selected in part because it targets one or more of these canonical pathways, and the stack as a whole creates overlapping coverage across the full landscape of cancer's signaling vulnerabilities.

The 13 Compounds: Why Each One Earns Its Place

1. 🌿 Fenbendazole — The Cornerstone

Fenbendazole is the anchor of the protocol — the compound with the broadest multi-mechanism anti-cancer activity and the most compelling repurposing story. Originally developed as a veterinary antiparasitic, fenbendazole has demonstrated remarkable anti-tumor activity across multiple cancer types through at least four distinct mechanisms:

• Microtubule disruption: Inhibits tubulin polymerization — the same mechanism as paclitaxel (Taxol) and vincristine, two of the most widely used chemotherapy drugs. This disrupts cell division across all rapidly dividing cancer cells regardless of type
• p53 stabilization: Restores function to the p53 tumor suppressor — the most commonly mutated gene in human cancer (~50% of all cancers). p53 is the cell's primary "guardian of the genome," triggering apoptosis when DNA damage is detected
• GLUT4 downregulation: Reduces glucose transporter expression, directly starving cancer cells of their primary fuel source via the Warburg effect
• Apoptosis induction: Triggers programmed cell death through multiple pathways independent of its microtubule effects

The human story that brought fenbendazole to public attention — Joe Tippens, diagnosed with terminal small cell lung cancer in 2016, given 3 months to live, who achieved complete remission after adding fenbendazole to his regimen — sparked a global wave of interest and a growing body of preclinical research. (Dogra et al., Scientific Reports, 2019)

Why it's the cornerstone: No other single compound simultaneously targets microtubule dynamics, p53, glucose metabolism, and apoptosis. It is the broadest-spectrum anti-cancer agent in the stack.

2. 🦟 Ivermectin — The Nobel Prize-Winning Synergist

Ivermectin, the 2015 Nobel Prize-winning antiparasitic, has emerged as one of the most mechanistically diverse anti-cancer compounds in the repurposed drug literature. Its anti-tumor mechanisms include:

• PAK1 kinase inhibition: PAK1 is overexpressed in many cancers and drives treatment resistance to multiple chemotherapy agents
• WNT-TCF pathway suppression: Disrupts cancer stem cell self-renewal signaling
• P-glycoprotein inhibition: Blocks the drug efflux pump that cancer cells use to expel chemotherapy — potentially enhancing the intracellular concentration of co-administered compounds including fenbendazole
• Immunogenic cell death induction: Triggers a form of cancer cell death that activates the immune system against the tumor
• Selective AML stem cell toxicity: Documented in Blood Cancer Journal (2018) — ivermectin selectively kills leukemia stem cells while sparing normal hematopoietic cells

Why it earns its place: Ivermectin's P-glycoprotein inhibition makes every other compound in the stack more effective by preventing cancer cells from pumping them out. It is the protocol's built-in bioavailability enhancer. (Juarez et al., Pharmacological Research, 2020)

3. 🍋 Liposomal Vitamin C (1,000mg) — The Pro-Oxidant Fuel Blocker

Vitamin C has a dual identity that is dose-dependent and often misunderstood:

• At low doses (dietary): acts as an antioxidant, protecting cells from oxidative damage
• At pharmacological doses (liposomal oral or IV): acts as a pro-oxidant, generating hydrogen peroxide selectively in cancer cells (which lack the catalase enzyme to neutralize it) while leaving normal cells unharmed

Additional mechanisms include HIF-1α inhibition (reducing tumor adaptation to hypoxia and VEGF-driven angiogenesis), collagen synthesis support (maintaining tissue integrity around tumors), and immune cell activation. Liposomal delivery dramatically increases oral bioavailability — achieving plasma concentrations approaching those of IV administration. (Padayatty et al., PNAS, 2004)

Why it earns its place: It is the only compound in the stack that selectively generates oxidative stress inside cancer cells — a mechanism entirely distinct from all other 12 compounds.

4. ☀️ Vitamin D3 + K2 (50,000 IU) — The Mortality Reducer

Vitamin D3 is arguably the most evidence-supported single supplement for cancer outcomes across all cancer types:

• Vitamin D receptor (VDR) is expressed on virtually all cancer cell types; D3 binding promotes cellular differentiation (converting malignant cells toward more mature, less proliferative phenotypes) and inhibits proliferation
• Low vitamin D status is consistently associated with higher cancer incidence, more aggressive disease, and worse survival across breast, colorectal, prostate, lung, and hematologic cancers
• A 2019 meta-analysis of 10 randomized controlled trials found vitamin D supplementation associated with a 13% reduction in cancer mortality
• D3 modulates immune function — supporting NK cell and T-cell activity critical for immune surveillance
• K2 (MK-7) is included to direct calcium away from soft tissues (preventing arterial calcification from high-dose D3) and toward bone — essential for safety at 50,000 IU dosing

Why it earns its place: No other compound has a 13% cancer mortality reduction signal across a meta-analysis of RCTs. It is the protocol's most evidence-supported mortality modifier. (Keum & Giovannucci, Annals of Oncology, 2014)

5. 🔩 Zinc (50mg) + Copper (2mg) — The Immune Activator

Zinc and copper are paired deliberately — both are essential trace minerals with distinct and complementary roles in cancer biology:

• Zinc: Essential for T-cell and NK cell function; supports p53 function (zinc-finger protein — p53 requires zinc to maintain its DNA-binding conformation); inhibits NF-κB inflammatory signaling; deficiency is common in cancer patients and associated with worse outcomes
• Copper: Required for the disulfiram-copper complex (CuET) mechanism when disulfiram is added as a repurposed pharmaceutical add-on — copper in the stack "primes" this mechanism. Also essential for superoxide dismutase (SOD) antioxidant enzyme function
• The 50mg zinc / 2mg copper ratio maintains the physiological zinc-to-copper balance — high-dose zinc alone depletes copper, so copper must be co-supplemented

Why it earns its place: Zinc addresses immune dysfunction (universal in cancer) and p53 support (relevant to ~50% of all cancers) simultaneously. The copper inclusion "activates" the disulfiram add-on mechanism.

6. 🌶️ Curcumin (600mg + Black Pepper) — The Anti-Inflammatory Amplifier

Curcumin is the most studied natural compound in oncology, with over 3,000 published studies. Its anti-cancer mechanisms are exceptionally broad:

• NF-κB inhibition: NF-κB is the master regulator of cancer-promoting inflammation and is constitutively activated in the majority of solid tumors and hematologic malignancies
• STAT3 inhibition: STAT3 drives immune evasion and treatment resistance across multiple cancer types
• BCL-2 downregulation: Promotes apoptosis in cancers that overexpress BCL-2 (CLL, follicular lymphoma, many solid tumors)
• PI3K/AKT/mTOR inhibition: Suppresses the growth signaling pathway activated in the majority of cancers
• Epigenetic modulation: Inhibits DNMT and HDAC enzymes, reprogramming cancer cell gene expression

Piperine (black pepper extract) increases curcumin bioavailability by up to 2,000% — without it, curcumin is poorly absorbed. This pairing is non-negotiable. (Aggarwal et al., Biochemical Pharmacology, 2006)

Why it earns its place: NF-κB inhibition alone justifies inclusion — NF-κB is activated in virtually every cancer type and drives both tumor progression and treatment resistance.

7. 🌱 CBD Oil (25mg/ml) — The Apoptosis Enhancer

Cannabidiol (CBD) interacts with the endocannabinoid system (ECS) — a regulatory network expressed throughout the body including on cancer cells — through CB1 and CB2 receptors as well as non-receptor mechanisms:

• CB2 receptor activation: Induces apoptosis via ceramide production in cancer cells; CB2 is overexpressed on many tumor types relative to normal tissue
• Anti-angiogenic effects: Reduces VEGF-driven tumor blood vessel formation
• Anti-proliferative effects: Demonstrated across breast, prostate, colon, lung, leukemia, and cervical cancer cell lines
• Anti-metastatic effects: Inhibits cancer cell migration and invasion
• Neuroprotective effects: Particularly relevant for brain cancer and for protecting neurological function during chemotherapy

Full Extract Cannabis Oil (FECO) — containing the full spectrum of cannabinoids, terpenes, and flavonoids — may produce synergistic entourage effects beyond isolated CBD. (Lukhele & Motadi, BMC Complementary and Alternative Medicine, 2016)

Why it earns its place: CBD's CB2-mediated apoptosis mechanism is entirely distinct from all other compounds in the stack — it adds a unique cell death pathway that complements rather than duplicates the others.

8. 🥛 Lactoferrin (500mg) — The Iron Chelator

Lactoferrin is an iron-binding glycoprotein found in breast milk, saliva, and mucosal secretions — one of the body's primary innate immune defense proteins. Its anti-cancer mechanisms are underappreciated:

• Iron chelation: Cancer cells have exceptionally high iron demand to support rapid DNA replication. Lactoferrin sequesters free iron, limiting tumor availability — exploiting a universal cancer vulnerability
• NK cell and macrophage activation: Directly activates innate immune cells critical for tumor surveillance
• Antiviral activity: Relevant for virus-associated cancers (EBV-associated lymphoma, HPV-associated cervical cancer, HBV/HCV-associated liver cancer)
• BBB transport: Lactoferrin receptors on brain endothelial cells enable receptor-mediated transcytosis — making it relevant for brain cancer and as a potential drug delivery vehicle

Why it earns its place: Iron chelation is a cancer vulnerability that no other compound in the stack addresses. Cancer cells' iron addiction makes lactoferrin's mechanism uniquely complementary. (Tsuda et al., Biochemistry & Cell Biology, 2002)

9. 🌑 Black Seed Oil (1,000mg) — The Detox Support

Black seed oil (Nigella sativa) contains thymoquinone (TQ) as its primary bioactive compound — one of the most studied natural anti-cancer agents in the Middle Eastern and Asian medical literature:

• Pro-apoptotic: Induces apoptosis across multiple cancer cell lines through both intrinsic (mitochondrial) and extrinsic (death receptor) pathways
• Akt/mTOR inhibition: Suppresses the PI3K/AKT/mTOR growth signaling axis
• NF-κB inhibition: Complementary to curcumin's NF-κB suppression — dual NF-κB inhibition provides more complete pathway blockade
• Liver detoxification support: Supports Phase I and II hepatic detoxification — critical for clearing carcinogenic metabolites and processing chemotherapy drugs
• Nephroprotective: Protects kidney function — particularly relevant for patients on nephrotoxic chemotherapy or with reduced kidney function

Why it earns its place: Black seed oil's liver and kidney protective properties are unique in the stack — no other compound provides this organ-protective function that is critical during chemotherapy. (Arafa et al., International Journal of Molecular Sciences, 2011)

10. 🍵 Green Tea Extract (500mg) — The OxPhos Disruptor

Green tea extract standardized to EGCG (epigallocatechin gallate) is one of the most mechanistically versatile natural compounds in oncology:

• VEGF inhibition: Anti-angiogenic — reduces tumor blood vessel formation
• BCL-2 inhibition: Pro-apoptotic — promotes cancer cell death in BCL-2-overexpressing tumors
• BTK inhibition: The same target as ibrutinib (approved for CLL and mantle cell lymphoma) — EGCG is a natural BTK inhibitor
• ASCT2 glutamine transporter suppression: Reduces glutamine uptake — starving cancer cells of their secondary fuel source
• OxPhos targeting in cancer stem cells: Disrupts oxidative phosphorylation in the cancer stem cell population responsible for recurrence
• Telomerase inhibition: Reduces cancer cell replicative immortality

A Phase II clinical trial (Shanafelt et al., Journal of Clinical Oncology, 2013) demonstrated EGCG stabilized or reduced lymphocyte counts in 69% of CLL patients — one of the strongest clinical signals for any natural compound in oncology. (Shanafelt et al., JCO, 2013)

Why it earns its place: EGCG is the only compound in the stack that simultaneously targets BTK, BCL-2, VEGF, glutamine transport, and cancer stem cell OxPhos — five distinct mechanisms in one compound.

11. 🌿 Milk Thistle (250mg) — The Liver Protector

Milk thistle (silymarin/silibinin) is the protocol's dedicated hepatoprotective agent — a role that is essential but often overlooked:

• Liver protection during chemotherapy: Most chemotherapy drugs are hepatotoxic; silymarin protects hepatocytes from drug-induced damage, potentially allowing higher chemotherapy doses to be tolerated
• Phase I/II detoxification support: Enhances the liver's ability to process and eliminate carcinogenic metabolites, environmental toxins, and chemotherapy breakdown products
• Direct anti-tumor activity: Silibinin has demonstrated anti-proliferative effects in prostate, breast, colon, lung, and bladder cancer cell lines — inhibiting cell cycle progression at G1/S checkpoint
• Anti-angiogenic: Inhibits VEGF-driven angiogenesis
• Anti-metastatic: Reduces MMP (matrix metalloproteinase) activity that cancer cells use to invade surrounding tissue

Why it earns its place: Liver protection during treatment is non-negotiable — a compromised liver cannot process chemotherapy, metabolize hormones, or eliminate toxins. Milk thistle is the protocol's safety net for the body's primary detoxification organ. (Zi et al., Cancer Research, 1998)

12. 🍊 Modified Citrus Pectin (5g powder) — The Spread Blocker

Modified citrus pectin (MCP) is a specially processed form of pectin that is small enough to be absorbed into the bloodstream and exert systemic effects. Its primary anti-cancer mechanism is galectin-3 inhibition:

• Galectin-3 inhibition: Galectin-3 is a protein that cancer cells use to adhere to blood vessel walls, evade immune destruction, and establish metastatic colonies. MCP competitively binds galectin-3, blocking these functions
• Anti-metastatic: By blocking galectin-3, MCP reduces cancer cell adhesion and metastatic spread — the process responsible for ~90% of cancer deaths
• Immune modulation: Galectin-3 also suppresses immune cell function; MCP's inhibition restores NK cell and T-cell activity
• Heavy metal detoxification: MCP binds heavy metals (lead, mercury, arsenic, cadmium) in the gut and bloodstream, supporting elimination — relevant given heavy metal exposure as a cancer risk factor

Dr. Isaac Eliaz (dreliaz.org) is the world's leading clinical researcher on MCP and galectin-3 in oncology, with multiple published clinical trials. (Eliaz et al., Integrative Cancer Therapies, 2007)

Why it earns its place: MCP is the only compound in the stack specifically targeting metastasis — the process that kills 90% of cancer patients. No other compound addresses galectin-3-mediated spread.

13. 🍄 Turkey Tail Mushroom (1,000mg) — The Immune Enhancer

Turkey tail (Trametes versicolor) is the most clinically studied medicinal mushroom in oncology. Its primary bioactive compounds — Polysaccharide-K (PSK) and Polysaccharide-P (PSP) — are approved cancer adjuncts in Japan and have been used alongside chemotherapy for decades:

• NK cell activation: Directly activates natural killer cells — the immune system's primary anti-tumor surveillance cells
• Dendritic cell maturation: Enhances antigen presentation, improving the immune system's ability to recognize and target cancer cells
• T-lymphocyte activation: Supports both CD4+ helper and CD8+ cytotoxic T-cell responses
• Gut microbiome support: Beta-glucans act as prebiotics, supporting the gut microbiome that educates the immune system
• Chemotherapy synergy: PSK has been shown to improve survival when combined with chemotherapy in gastric, colorectal, and breast cancer in Japanese clinical trials

A 2012 study funded by the NIH (Standish et al.) demonstrated that turkey tail supplementation significantly enhanced immune function in breast cancer patients receiving conventional treatment. (Standish et al., ISIO, 2008)

Why it earns its place: Immune dysfunction is universal in cancer — every cancer type suppresses immune surveillance. Turkey tail is the protocol's dedicated immune restoration agent, with the strongest clinical evidence base of any medicinal mushroom in oncology.

How the 13 Work Together: System-Level Synergies

The Functional 13 is not simply 13 compounds taken simultaneously — it is a system with deliberate synergies:

Beyond the Foundation: Additional Supplements That Play a Key Role

The Functional 13 is the starting point — not the ceiling. Depending on cancer type, treatment status, and individual biology, additional supplements can be layered on top to address specific vulnerabilities. These are organized by their primary mechanism:

🧬 Mitochondrial & Energy Metabolism Support

• CoQ10 (200–400mg): Essential for mitochondrial electron transport chain function; protects against chemotherapy-induced cardiotoxicity (particularly anthracyclines like doxorubicin); reduces fatigue; anti-tumor activity in breast cancer models
• PQQ (Pyrroloquinoline Quinone, 20mg): Stimulates mitochondrial biogenesis; synergistic with CoQ10; neuroprotective during brain cancer treatment
• Alpha-Lipoic Acid (ALA, 600mg): Universal antioxidant (both fat and water soluble); regenerates vitamins C and E; supports mitochondrial function; Dr. Burt Berkson has published case reports combining ALA with LDN in cancer contexts
• NAD+ Precursors (NMN or NR, 500mg): Restore NAD+ levels depleted by cancer and chemotherapy; support DNA repair via PARP enzymes; activate sirtuins (SIRT1) that regulate cancer cell metabolism
• Berberine (500mg): AMPK activator — the metabolic master switch that opposes mTOR; reduces insulin resistance; inhibits mitochondrial Complex I in cancer cells; overlaps with metformin mechanism

🛡️ Immune System Amplifiers

• AHCC (Active Hexose Correlated Compound, 3g): Medicinal mushroom extract with specific clinical trial data for NK cell activation and HPV clearance; studied in ovarian, liver, and cervical cancer contexts
• Beta-Glucans (500mg): Isolated beta-1,3/1,6-glucans from yeast or mushrooms; directly activate macrophages and NK cells via Dectin-1 receptor; synergistic with checkpoint inhibitor immunotherapy
• Astragalus (500mg): Traditional Chinese medicine immune tonic; activates T-cells and NK cells; adaptogenic; may enhance immunotherapy response; supports kidney function
• Medicinal Mushroom Blend: Reishi (immune modulation, anti-angiogenic), shiitake (lentinan — approved cancer adjunct in Japan), lion's mane (NGF stimulation — neuroprotective, particularly for brain cancer)
• Quercetin (500mg): Flavonoid with senolytic activity (clears senescent "zombie" cells that fuel tumor microenvironment); inhibits HPV E6/E7 oncoproteins; synergistic with EGCG; PI3K/AKT inhibition

🔥 Anti-Inflammatory Amplifiers

• Omega-3 Fatty Acids EPA/DHA (2–4g): Reduce systemic inflammation via prostaglandin E2 suppression; support immune cell membrane fluidity; associated with improved cancer survival in multiple cohort studies; anti-cachexia (muscle wasting) effects
• Boswellic Acids / Boswellia serrata (400mg): 5-LOX inhibitor — reduces leukotriene-driven inflammation; reduces peritumoral cerebral edema (RCT evidence in brain tumor patients); anti-proliferative in multiple cancer types
• Resveratrol (500mg): SIRT1 activator; inhibits Wnt/β-catenin signaling; crosses blood-brain barrier; anti-estrogenic effects relevant to hormone-sensitive cancers; synergistic with curcumin
• Astaxanthin (4–12mg): Carotenoid antioxidant (6,000x stronger than vitamin C by some measures); anti-angiogenic; nephroprotective; anti-inflammatory via NF-κB suppression

🧪 Hormone & Estrogen Metabolism

• DIM (Diindolylmethane, 200mg): Promotes healthy estrogen metabolism via the 2-OH pathway; reduces carcinogenic 4-OH and 16-OH estrone metabolites; directly relevant to breast, ovarian, uterine, and prostate cancers
• I3C (Indole-3-Carbinol, 200mg): Precursor to DIM; additional anti-cancer mechanisms including CDK inhibition; found in cruciferous vegetables
• Calcium D-Glucarate (500mg): Inhibits beta-glucuronidase — the enzyme that reactivates estrogen in the gut for reabsorption; supports estrogen elimination
• Melatonin (20–180mg at bedtime): At pharmacological doses: inhibits aromatase (reducing local estrogen production); modulates estrogen receptor activity; anti-tumor effects across multiple cancer types; Dr. Paolo Lissoni published multiple clinical trials showing improved survival with melatonin + IL-2 in advanced cancers

🦴 Bone & Structural Support

• Magnesium (400mg): Cofactor for 300+ enzymatic reactions; supports DNA repair; reduces chemotherapy-induced neuropathy; commonly depleted by cancer and treatment
• Selenium (200mcg): Essential for glutathione peroxidase (antioxidant enzyme); anti-tumor activity in prostate, colorectal, and lung cancer; supports thyroid function during cancer treatment
• Strontium (680mg as strontium citrate): Bone-seeking mineral; reduces bone metastasis pain; supports bone density during hormone-suppressive therapy (aromatase inhibitors, ADT)

Repurposed Pharmaceuticals: A Comprehensive Map by Mechanism

Beyond the Functional 13 and supplemental stack, a growing body of evidence supports the use of repurposed pharmaceuticals — medications originally developed for other conditions — as adjunctive tools in cancer support. These are organized by their primary mechanism class. All repurposed pharmaceutical use should be supervised by a physician familiar with this literature.

🔬 Antiparasitic / Anthelmintic Agents

💊 Metabolic / Diabetes Agents

🦟 Antimalarial Agents

🍺 Alcohol Dependence Agents

💉 Opioid Antagonists

🫀 Cardiovascular / Antiplatelet Agents

🧠 Neurological / Psychiatric Agents

🦠 Antibiotic Agents — Mitochondrial Targeting

🌙 Hormonal / Circadian Agents

How to Use This Framework: Personalization Principles

The Functional 13 is the universal starting point — applicable across all cancer types. Personalization happens in two layers on top of this foundation:

Layer 1 — Cancer-type specific add-ons: Each cancer type has specific biological vulnerabilities (e.g., HIF-1α in clear cell RCC, BCL-2 in CLL, HPV E6/E7 in cervical cancer, EGFR in GBM) that warrant targeted additions from the supplement and repurposed pharmaceutical lists above.

Layer 2 — Treatment-phase specific add-ons:

• During chemotherapy: Prioritize liver protection (milk thistle), mitochondrial support (CoQ10), immune support (turkey tail, AHCC), and nausea/fatigue management (ginger, CoQ10, melatonin)
• During radiation: Prioritize antioxidant support (vitamin C, vitamin E, selenium), anti-inflammatory compounds (curcumin, boswellia), and neuroprotection for brain radiation (lion's mane, omega-3s)
• During immunotherapy: Prioritize immune amplifiers (turkey tail, beta-glucans, AHCC, LDN) while being cautious with strong immunosuppressants; avoid compounds that may blunt immune activation
• During targeted therapy: Prioritize compounds that address resistance mechanisms (HCQ for autophagy resistance, berberine for mTOR resistance, ivermectin for P-gp-mediated resistance)
• Watch-and-wait / prevention / remission maintenance: Full Functional 13 stack plus cancer-type specific add-ons; metabolic optimization (ketogenic or low-glycemic diet, intermittent fasting); stress reduction; sleep optimization

Important Considerations & Safety Notes

• This protocol is adjunctive, not alternative: The Functional 13 is designed to work alongside conventional oncology care — surgery, chemotherapy, radiation, targeted therapy, and immunotherapy — not to replace it
• Drug interactions: Several compounds (particularly CBD, EGCG, and curcumin) interact with CYP450 liver enzymes that metabolize many chemotherapy drugs. Always disclose all supplements to your oncologist
• Timing matters: Some antioxidants may theoretically reduce the efficacy of radiation or certain chemotherapy drugs that work through oxidative mechanisms. Discuss timing of supplements relative to treatment with your oncologist
• Repurposed pharmaceuticals require physician supervision: All repurposed drugs discussed in this article require a prescription and should be managed by a physician familiar with this literature
• Individual variation: Genetic polymorphisms (particularly in CYP450 enzymes, MTHFR, and VDR) affect how individuals metabolize and respond to these compounds. Functional medicine testing can guide personalization
• Quality matters: Supplement quality varies enormously. Prioritize third-party tested products, liposomal formulations where available, and standardized extracts with verified active compound content

📋 Practitioner Resources & Further Reading:

• Cancer Landscape Overview — The Cancer Landscape: Types, Causes, Symptoms & Natural Holistic Support Approaches — start here for the full overview of cancer types, shared biology, and integrative strategies
• FLCCC Alliance Cancer Protocols: covid19criticalcare.com
• LDN Research Trust: ldnresearchtrust.org
• Dr. Dustin Sulak / Cannabinoid Medicine: healer.com
• Dr. Isaac Eliaz — Modified Citrus Pectin & Galectin-3: dreliaz.org
• Dr. Thomas Seyfried — Metabolic Cancer Therapy: Cancer as a Metabolic Disease (book)
• Dr. Michael Lisanti — Mitochondrial Targeting: University of Salford, Oncotarget publications
• Dr. Ian Zagon — OGF/LDN in Cancer: Penn State College of Medicine
• Dr. Paolo Lissoni — Melatonin in Oncology: Multiple publications in Oncology, British Journal of Cancer
• Hanahan D & Weinberg RA. (2022). Hallmarks of Cancer: New Dimensions. Cancer Cell.
• Dogra N et al. (2019). Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death. Scientific Reports.
• Juarez M et al. (2020). Ivermectin as an antitumor agent. Pharmacological Research.
• Shanafelt TD et al. (2013). Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic CLL. Journal of Clinical Oncology.
• Eliaz I et al. (2007). The effect of modified citrus pectin on urinary excretion of toxic elements. Integrative Cancer Therapies.
• Standish LJ et al. (2008). Trametes versicolor mushroom immune therapy in breast cancer. ISIO.
• Padayatty SJ et al. (2004). Vitamin C pharmacokinetics: implications for oral and intravenous use. PNAS.
• Keum N & Giovannucci E. (2014). Vitamin D supplements and cancer incidence and mortality. Annals of Oncology.
• Skrott Z et al. (2017). Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature.

Conclusion

The Functional 13 Protocol represents the most rational, evidence-informed starting point for integrative cancer support available today. By simultaneously addressing the broadest possible range of cancer's core biological vulnerabilities — from glucose metabolism and mitochondrial function to immune evasion, metastasis, and epigenetic reprogramming — it creates a multi-layered defense that is far more difficult for cancer to circumvent than any single intervention.

It is a foundation, not a ceiling. The additional supplements and repurposed pharmaceuticals mapped in this article allow practitioners and patients to build a personalized protocol on top of this foundation — targeting the specific biology of their cancer type, treatment phase, and individual physiology.

Work with an integrative oncologist or functional medicine physician to build your personalized protocol. The evidence base is growing rapidly — and the patients who combine the best of conventional oncology with a rigorous integrative approach are achieving outcomes that neither approach could deliver alone.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis, treatment, and personalized care decisions. Nothing in this article should replace or delay conventional medical evaluation and treatment.